Highlights
The global Oncology Based Molecular Diagnostic market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Oncology Based Molecular Diagnostic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Oncology Based Molecular Diagnostic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Oncology Based Molecular Diagnostic in Breast Cancer is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Oncology Based Molecular Diagnostic include Abbott, Bayer Healthcare, Beckton Dickinson, Cepheid, Dako, Hologic, Qiagen, Roche and Siemens Healthineers, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oncology Based Molecular Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Based Molecular Diagnostic.
The Oncology Based Molecular Diagnostic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oncology Based Molecular Diagnostic market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Based Molecular Diagnostic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Abbott
Bayer Healthcare
Beckton Dickinson
Cepheid
Dako
Hologic
Qiagen
Roche
Siemens Healthineers
Sysmex
Segment by Type
Instruments
Reagents
Segment by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer
Kidney Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Based Molecular Diagnostic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Based Molecular Diagnostic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Instruments
1.2.3 Reagents
1.3 Market by Application
1.3.1 Global Oncology Based Molecular Diagnostic Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Breast Cancer
1.3.3 Prostate Cancer
1.3.4 Colorectal Cancer
1.3.5 Cervical Cancer
1.3.6 Liver Cancer
1.3.7 Lung Cancer
1.3.8 Blood Cancer
1.3.9 Kidney Cancer
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Based Molecular Diagnostic Market Perspective (2018-2029)
2.2 Oncology Based Molecular Diagnostic Growth Trends by Region
2.2.1 Global Oncology Based Molecular Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Oncology Based Molecular Diagnostic Historic Market Size by Region (2018-2023)
2.2.3 Oncology Based Molecular Diagnostic Forecasted Market Size by Region (2024-2029)
2.3 Oncology Based Molecular Diagnostic Market Dynamics
2.3.1 Oncology Based Molecular Diagnostic Industry Trends
2.3.2 Oncology Based Molecular Diagnostic Market Drivers
2.3.3 Oncology Based Molecular Diagnostic Market Challenges
2.3.4 Oncology Based Molecular Diagnostic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Based Molecular Diagnostic Players by Revenue
3.1.1 Global Top Oncology Based Molecular Diagnostic Players by Revenue (2018-2023)
3.1.2 Global Oncology Based Molecular Diagnostic Revenue Market Share by Players (2018-2023)
3.2 Global Oncology Based Molecular Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncology Based Molecular Diagnostic Revenue
3.4 Global Oncology Based Molecular Diagnostic Market Concentration Ratio
3.4.1 Global Oncology Based Molecular Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Based Molecular Diagnostic Revenue in 2022
3.5 Oncology Based Molecular Diagnostic Key Players Head office and Area Served
3.6 Key Players Oncology Based Molecular Diagnostic Product Solution and Service
3.7 Date of Enter into Oncology Based Molecular Diagnostic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Based Molecular Diagnostic Breakdown Data by Type
4.1 Global Oncology Based Molecular Diagnostic Historic Market Size by Type (2018-2023)
4.2 Global Oncology Based Molecular Diagnostic Forecasted Market Size by Type (2024-2029)
5 Oncology Based Molecular Diagnostic Breakdown Data by Application
5.1 Global Oncology Based Molecular Diagnostic Historic Market Size by Application (2018-2023)
5.2 Global Oncology Based Molecular Diagnostic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Oncology Based Molecular Diagnostic Market Size (2018-2029)
6.2 North America Oncology Based Molecular Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Oncology Based Molecular Diagnostic Market Size by Country (2018-2023)
6.4 North America Oncology Based Molecular Diagnostic Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncology Based Molecular Diagnostic Market Size (2018-2029)
7.2 Europe Oncology Based Molecular Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Oncology Based Molecular Diagnostic Market Size by Country (2018-2023)
7.4 Europe Oncology Based Molecular Diagnostic Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncology Based Molecular Diagnostic Market Size (2018-2029)
8.2 Asia-Pacific Oncology Based Molecular Diagnostic Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Oncology Based Molecular Diagnostic Market Size by Region (2018-2023)
8.4 Asia-Pacific Oncology Based Molecular Diagnostic Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncology Based Molecular Diagnostic Market Size (2018-2029)
9.2 Latin America Oncology Based Molecular Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Oncology Based Molecular Diagnostic Market Size by Country (2018-2023)
9.4 Latin America Oncology Based Molecular Diagnostic Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Based Molecular Diagnostic Market Size (2018-2029)
10.2 Middle East & Africa Oncology Based Molecular Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Oncology Based Molecular Diagnostic Market Size by Country (2018-2023)
10.4 Middle East & Africa Oncology Based Molecular Diagnostic Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott Oncology Based Molecular Diagnostic Introduction
11.1.4 Abbott Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.1.5 Abbott Recent Development
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Detail
11.2.2 Bayer Healthcare Business Overview
11.2.3 Bayer Healthcare Oncology Based Molecular Diagnostic Introduction
11.2.4 Bayer Healthcare Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.2.5 Bayer Healthcare Recent Development
11.3 Beckton Dickinson
11.3.1 Beckton Dickinson Company Detail
11.3.2 Beckton Dickinson Business Overview
11.3.3 Beckton Dickinson Oncology Based Molecular Diagnostic Introduction
11.3.4 Beckton Dickinson Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.3.5 Beckton Dickinson Recent Development
11.4 Cepheid
11.4.1 Cepheid Company Detail
11.4.2 Cepheid Business Overview
11.4.3 Cepheid Oncology Based Molecular Diagnostic Introduction
11.4.4 Cepheid Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.4.5 Cepheid Recent Development
11.5 Dako
11.5.1 Dako Company Detail
11.5.2 Dako Business Overview
11.5.3 Dako Oncology Based Molecular Diagnostic Introduction
11.5.4 Dako Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.5.5 Dako Recent Development
11.6 Hologic
11.6.1 Hologic Company Detail
11.6.2 Hologic Business Overview
11.6.3 Hologic Oncology Based Molecular Diagnostic Introduction
11.6.4 Hologic Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.6.5 Hologic Recent Development
11.7 Qiagen
11.7.1 Qiagen Company Detail
11.7.2 Qiagen Business Overview
11.7.3 Qiagen Oncology Based Molecular Diagnostic Introduction
11.7.4 Qiagen Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.7.5 Qiagen Recent Development
11.8 Roche
11.8.1 Roche Company Detail
11.8.2 Roche Business Overview
11.8.3 Roche Oncology Based Molecular Diagnostic Introduction
11.8.4 Roche Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.8.5 Roche Recent Development
11.9 Siemens Healthineers
11.9.1 Siemens Healthineers Company Detail
11.9.2 Siemens Healthineers Business Overview
11.9.3 Siemens Healthineers Oncology Based Molecular Diagnostic Introduction
11.9.4 Siemens Healthineers Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.9.5 Siemens Healthineers Recent Development
11.10 Sysmex
11.10.1 Sysmex Company Detail
11.10.2 Sysmex Business Overview
11.10.3 Sysmex Oncology Based Molecular Diagnostic Introduction
11.10.4 Sysmex Revenue in Oncology Based Molecular Diagnostic Business (2018-2023)
11.10.5 Sysmex Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbott
Bayer Healthcare
Beckton Dickinson
Cepheid
Dako
Hologic
Qiagen
Roche
Siemens Healthineers
Sysmex
*If Applicable.